PAUL N FIEDLER, MD
Medical Practice at Chapel St, New Haven, CT

6444436, Sep 3, 2002

Feb 22, 2000

09/507635

David L. Rimm - Brandford CT 06405
Paul Fiedler - New Haven CT 06515
Robert A. Levine - Guilford CT 06437
Stephen C. Wardlaw - Lyme CT 06371

G01N 33574

435 4051, 356 36, 435 71, 435 722, 435 723, 435 724, 436 63, 436 64, 436523, 436810

A method for analyzing blood enables one to isolate, detect, enumerate and confirm under magnification the presence or absence of target cancer cells and/or hematologic progenitor cells, or other rare events which are known to circulate in blood. The analysis is performed in a sample of centrifuged anticoagulated whole blood. The analysis involves both morphometric and epitopic examination of the blood sample while the blood sample is disposed in a centrifuged blood sampling container. The epitopic analysis of the presence or absence of cancer cells relies on the detection of epitopes which are known to be present on cancer cells and not on normal circulating blood cells; and the epitopic analysis of the presence or absence of hematologic progenitor cells relies on the detection of epitopes which are known to be present on hematologic progenitor cells and not on normal circulating blood cells. The targeted epitopes on the target cell types are epitopes which are also known to be absent on normal circulating blood cells; and the target cancer cell epitopes are epitopes which are known to be absent on target hematologic progenitor cells. Fluorophors with distinct emissions are coupled with antibodies which are directed against the targeted epitopes.

6670197, Dec 30, 2003

Mar 5, 2001

09/800344

David L. Rimm - Branford CT 06405
Stephen C. Wardlaw - Lyme CT 06371
Robert A. Levine - Guilford CT 06437
Paul Fiedler - New Haven CT 06515

G01N 33543

436518, 356 36, 435 71, 435 722, 435 723, 435 724, 436 63, 436 64, 436523

This method for analyzing blood enables one to isolate, detect, enumerate and confirm under magnification the presence or absence of fragments of target analyte cancer cells which are circulating in blood. The analysis is performed in a sample of centrifuged anticoagulated whole blood. The analysis of the presence or absence of fragments of cancer cells relies on the detection of external or internal binding sites which are known to be present only in or on tumorous cancer cells. Fluorophors with distinct wavelength emissions are coupled with antibodies, or other binding moieties such as complementary nucleotide sequences, which antibodies are directed against the epithelial cell fragment membrane binding sites, such as internal or external surface epitopes on the cell fragments, or internal binding sites on cell organelles; and which nucleotide sequences are complementary to portions of cell fragment RNA and/or DNA. The labled binding agents are humoric or soluble in the blood sample. The labeled fluorometric binding site-specific materials may be coupled to small plastic beads which have a density or specific gravity that is preferably greater than the specific gravity or density of the red blood cells.

6911315, Jun 28, 2005

Jan 10, 2002

10/042016

David L. Rimm - Branford CT, US
Paul Fiedler - New Haven CT, US
Robert A. Levine - Guilford CT, US
Stephen C. Wardlaw - Lyme CT, US

G01N033/53

435 722, 435 71, 435 723, 435 724, 436 63, 436 64, 436523, 436536, 436538

A method for analyzing blood enables one to isolate, detect, enumerate and confirm under magnification the presence of target cells which have expressed surface epitopes that indicate intracellular infection by various viruses or other infectious agents, and also cells which have expressed surface epitopes that indicate the presence of non-infectious medical conditions. The analysis involves the examination of cells in the blood sample for the presence or absence of particular surface epitopes while the blood sample is disposed in a centrifuged blood sampling container. The epitopic analysis for the presence or absence of infected cells, or cells which indicate the presence of non-infectious medical conditions relies on the detection of known target expressed epitopes. The target epitopes on the target cell types are epitopes which are also known to be absent on normal circulating cells in the blood. Fluorophores or other labels with distinct wavelength emissions are coupled with specific binding agents such as lectins, antibodies, aptamers, or the like, which are directed against the target expressed epitopes.

7129056, Oct 31, 2006

Jun 20, 2005

11/155856

David L. Rimm - Branford CT, US
Paul Fiedler - New Haven CT, US
Robert A. Levine - Guilford CT, US
Stephen C. Wardlaw - Lyme CT, US

G01N 33/53

435 724, 435 72, 435 721, 436 63, 436 64, 436165, 436810

A method for analyzing blood enables one to isolate, detect, enumerate and confirm under magnification the presence of target cells which have expressed surface epitopes that indicate intracellular infection by various viruses or other infectious agents, and also cells which have expressed surface epitopes that indicate the presence of non-infectious medical conditions. The analysis involves the examination of cells in the blood sample for the presence or absence of particular surface epitopes while the blood sample is disposed in a centrifuged blood sampling container. The epitopic analysis for the presence or absence of infected cells, or cells which indicate the presence of non-infectious medical conditions relies on the detection of known target expressed epitopes. The target epitopes on the target cell types are epitopes which are also known to be absent on normal circulating cells in the blood. Fluorophores or other labels with distinct wavelength emissions are coupled with specific binding agents such as lectins, antibodies, aptamers, or the like, which are directed against the target expressed epitopes.

5331973, Jul 26, 1994

Mar 15, 1993

8/031533

Paul N. Fiedler - New Haven CT
Robert A. Levine - Guilford CT
Stephen C. Wardlaw - Branford CT

A61B 500

128760

The specification discloses a method for enhancing the reliability of screening tests used for detecting the presence or absence of chemical markers associated with gastrointestinal cancer. The method comprises the steps of providing a laxative purge for administration to a patient, collecting a watery fecal sample and then applying the watery fecal sample to a test medium having an indicator to indicate the presence of chemical markers associated with gastrointestinal cancer, if there. Two alternative methods are suggested for obtaining a watery fecal sample. In a first embodiment, the purge is administered to the patient following a recent bowel movement and the first watery post-purge bowel movement is collected. In a second embodiment, the purge is administered to the patient, the first post-purge bowel movement is discarded and the second watery post-purge bowel movement is collected.

6197523, Mar 6, 2001

Nov 24, 1997

8/976886

David L. Rimm - Branford CT
Robert A. Levine - Guilford CT
Stephen C. Wardlaw - Highrock, Lyme CT
Paul Fiedler - New Haven CT

G01N 33574

435 71

A method for analyzing blood enables one to isolate, detect, enumerate and confirm under magnification the presence or absence of target cancer cells and/or hematologic progenitor cells which are known to circulate in blood. The analysis is performed in a sample of centrifuged anticoagulated whole blood. The analysis involves both morphometric and epitopic examination of the blood sample while the blood sample is disposed in a centrifuged blood sampling tube. The epitopic analysis of the presence or absence of cancer cells relies on the detection of epitopes which are known to present only on cancer cells; and the epitopic analysis of the presence or absence of hematologic progenitor cells relies on the detection of epitopes which are known to present only on hematologic progenitor cells. The targeted epitopes on the target cell types are epitopes which are also known to be absent on normal circulating blood cells; and the target cancer cell epitopes are epitopes which are known to be absent on target hematologic progenitor cells. Fluorophors with distinct emissions are coupled with antibodies which are directed against the targeted epitopes.

5496704, Mar 5, 1996

Sep 26, 1994

8/312513

Paul Fiedler - New Haven CT
Robert A. Levine - Guilford CT
Stephen C. Wardlaw - Old Saybrook CT

G01N 33569

435 722

A biological sample such as feces, sputum, cervical tissue, pleural fluids, exudates, cytologic specimens, or the like, is tested for the presence or absence of: ova; parasites; microorganisms; inflammatory, neoplastic tissue cells; or other target materials which are indicative of infestation, disease or infection. The sample is mixed with a buffer fluid and placed in a transparent tube which contains a volume-constricting cylindrical insert for gravimetric separation of components of the sample. The mixture is centrifuged, and the annular space between the insert and tube bore is examined under magnification for the presence of the target materials.

5252460, Oct 12, 1993

Oct 28, 1991

7/783397

Paul N. Fiedler - New Haven CT
Stephen C. Wardlaw - Old Saybrook CT
Robert A. Levine - Guilford CT

G01N 33537, G01N 33538

435 722

A biologic sample such as feces, sputum, cervical tissue, pleural fluids, exudates, cytologic specimens, or the like, is tested for the presence or absence of: ova; parasites; microorganisms; inflammatory, neoplastic tissue cells; or other target materials which are indicative of infestation, disease or infection. The sample is mixed with a buffer fluid and placed in a transparent tube which contains a volume-constricting cylindrical insert for gravimetric separation of components of the sample. The mixture is centrifuged, and the annular space between the insert and tube bore is examined under magnification for the presence of the target materials.